News Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Real-time Estimate Cboe BZX Other stock markets 01:25:03 03/05/2024 am IST			5-day change	1st Jan Change
2.305 ^USD	+6.22%		+10.48%	-66.47%

29/04	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	MT
18/04	Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	30/04	MT
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma	29/04	GL
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	19/04	MT
Immix Biopharma on Track to Dose NXC-201 Patients in United States	18/04	GL
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18/04	CI
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	16/04	AQ
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15/04	AQ
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03	GL
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03	AQ
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20/03	CI
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative	06/03	AQ
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03	GL
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03	AQ
Immix Biopharma 12 Month Review Progress Update	21/02	AQ
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	09/02	GL
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	09/02	AQ
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02	GL
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02	AQ
Immix Biopharma Prices $15 Million Stock Offering	06/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Summary

Filters